In a real-world registry study involving 181 patients with advanced NSCLC harboring EGFR exon 20 insertions, the most common first-line therapy was platinum-based chemotherapy (n = 111, 61.3%), which resulted in a median PFS of 6.6 months. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.